Monograph
C09CA02 - Eprosartan |
Not porphyrinogenic |
NP |
Rationale
Poorly absorbed, not metabolised.
Chemical description
Angiotensin II receptor antagonist. Weak inhibitor of CYP 2C9 in vitro. Biovailability only 13 % dependent on poor absorbtion. Excreted in unchanged form.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Teveten 400, filmomhulde tabletten 400 mg · Teveten 600, filmomhulde tabletten 600 mg 
Teveten 600 mg compr. pellic. 
Eprosartan · Eprosartan Mylan Pharmaceuticals 600 mg Comprimidos Recubiertos con Pelicula efg · Futuran · Navixen · Navixen 600 mg Comprimidos Recubiertos con pel?Cula · REGULATEN 600 mg COMPRIMIDOS RECUBIERTOS CON PELICULA · Tevetens 
Tevetenz 
Eprosartan · Teveten 
Teveten 
Teveten 
Teveten 
Teveten
© NAPOS 2025